BVXV BiondVax Pharmaceuticals Ltd.

0  -1%
Previous Close 6.45
Open 0.00
Price To book 2.88
Market Cap 21.51M
Shares 3,377,000
Volume 575
Short Ratio 1.44
Av. Daily Volume 68,902

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b enrollment commenced March 2016. Last patient visit September, 2016. Data due in "coming months". Estimate 1H 2017.
Universal flu vaccine

Latest News

  1. BiondVax Announces Fourth Quarter and Full Year 2016 Financial Results and Update
  2. BiondVax Gets Approval to Build Plant in Israel
  3. BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine
  4. BiondVax Publishes Regulatory Approval Strategy for Novel Universal Flu Vaccines in Future Virology Journal
  5. BVXV: New Publication Shows M-001 Incites Immune Protection Against Current and Future Influenza Strains
  6. Back to the Future: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't yet Exist
  7. BiondVax Receives $US 2.8 Million Investment From Angels High Tech Investments Ltd.
  8. BVXV: Phase 2b Trial Shows M-001 is Safe and Well Tolerated
  9. BiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate is Safe and Well Tolerated
  10. BiondVax Announces Third Quarter 2016 Financial Results and Update
  11. Highly Pathogenic Bird Flu Spreading Across Europe and Asia; BiondVax’s Universal Flu Vaccine Candidate Also Covers these Potential Pandemic Strains
  12. BiondVax Phase 2b European Trial: Last Patient Out
  13. Professor Shai Ashkenazi Appointed to BiondVax's Scientific Advisory Board
  14. BiondVax Announces Second Quarter 2016 Financial Results and Update
  15. BiondVax Invited to WHO Influenza Vaccine Meeting
  16. BVXV: Update on First Quarter Financials; Results from Phase 2b Trial of M-001 Expected at the End of 2016…
  17. BiondVax CEO to Present Universal Flu Vaccine Technology at BIO International Convention
  18. BiondVax Announces First Quarter 2016 Financial Results and Update
  19. BiondVax to Present Tomorrow at Joseph Gunner Pioneers 2016 Conference
  20. BVXV: Phase 2b Clinical Trial of M-001 Fully Enrolled; Results Expected in Late 2016 or Early 2017…